<DOC>
	<DOCNO>NCT00816413</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Removing T cell donor cell transplant give cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I/II trial study side effect give donor stem cell transplant pentostatin total-body irradiation see well work treat patient hematological cancer .</brief_summary>
	<brief_title>Donor Stem Cell Transplant , Pentostatin , Total-Body Irradiation Treating Patients With Hematological Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine safety pentostatin low-dose total body irradiation follow T-cell-reduced unrelated donor peripheral blood stem cell transplantation , term regimen-related toxicity , patient hematological malignancy . - To evaluate efficacy regimen , measure engraftment rate establishment donor hematopoietic chimerism , patient . Secondary - To determine incidence acute chronic graft-versus-host disease patient treat regimen . OUTLINE : - Reduced-intensity preparative regimen : Patients receive pentostatin IV 30 minute daily day -10 -8 undergo low-dose total-body irradiation day -1 . - Unrelated donor peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo T-cell-reduced donor PBSCT day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive cyclosporine IV 2 hour twice daily day -1 , 0 , 1 orally twice daily day 2-70 follow taper absence GVHD . Patients also receive oral mycophenolate mofetil twice daily day 0-27 followed taper . Patients undergo bone marrow aspirate biopsy blood sample collection periodically laboratory study . Samples analyze cytokine ( i.e. , IL-6 , TNF-γ , IL-1β , IL-10 ) ELISA ; phenotypic , molecular , functional analysis immunologic reconstitution marker ( i.e. , PHA , IL-2 , IL-4 , IL-10 , IL-12 , Fas , FasL , TNF , TGF-β , IFN-γ ) flow cytometry ; cytogenetics FISH . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis confirm hematological malignancy relapse high risk relapsing , include follow : Acute myeloid leukemia ( AML ) meeting follow criterion : Antecedent hematologic disorder Therapy relate Primary induction failure In first complete remission ( CR1 ) poorrisk cytogenetics , define follow : del ( 5q ) /5 del ( 7q ) /7 abn ( 3q ) ( 6 ; 9 ) del ( 20q ) del ( 17p ) +13 Complex karyotype ( 9 ; 22 ) = 11q23 rearrangement In second complete remission ( CR2 ) great Acute lymphoblastic leukemia meeting follow criterion : In CR1 WBC &gt; 50,000/mm³ diagnosis In CR1 poorrisk cytogenetics ( i.e. , [ 9 ; 22 ] , [ 1 ; 19 ] , [ 4 ; 11 ] ) AND meet least 1 follow criterion : = 1975 year age AND receive prior highdose chemotherapy , totalbody irradiation ( TBI ) , radiation dose precludes administration 12 Gy TBI = 5075 year age = 1975 year age hematopoietic stem cell transplantation ( HSCT ) comorbidity index ≥ 3 CNS testicular involvement diagnosis No CR within 4 week initial treatment Primary induction failure In CR2 great Myelodysplastic syndrome meet follow criterion : Intermediate2 highrisk category determine International Prognostic Scoring System Not consider candidate intensive standard chemotherapy HSCT Chronic myelogenous leukemia meeting follow criterion : First chronic phase AND &lt; 40 year age First chronic phase AND hematologic response 3 month imatinib mesylate therapy First chronic phase AND never achieve complete cytogenetic response imatinib mesylate therapy First chronic phase AND loss previously document response Accelerated phase Blast crisis phase Chronic myeloproliferative disorder ( i.e. , polycythemia vera , essential thrombocythemia , myelofibrosis ) Bone marrow blast &gt; 5 % and/or evidence progression acute leukemia Chronic myelomonocytic leukemia Severe aplastic anemia Failed prior antithymocyte globulin cyclosporine immunosuppressive therapy Mantle cell lymphoma meet follow criterion : In CR1 In first partial remission ( PR1 ) In CR 2 great In second PR ( PR2 ) great Indolent nonHodgkin lymphoma OR chronic lymphocytic leukemia meeting either follow criterion : In CR 2 great In PR 2 great Lymphoblastic lymphoma In CR1 great Must minimal residual disease define either follow : No 5 % blast blood and/or bone marrow ( patient acute leukemia/MDS ) No bulky adenopathy ( &gt; 5 cm mass ) and/or &lt; 20 % bone marrow involvement lymphoma ( patient lymphoma ) No progressive disease within 8 week recent prior therapy OR within 12 week prior autologous HSCT No active CNS malignancy ( i.e. , know positive CSF cytology parenchymal lesion visible CT scan MRI ) HLAmatched unrelated peripheral blood stem cell donor available Meets University Nebraska Medical Center 's National Marrow Donor Program 's criterion donor Matched 7/8 8/8 HLAA , B , C , DRβ1 loci molecular type If match allele level , suitability donation require discussion approval principal investigator Not identical twin PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Creatinine clearance ≥ 55 mL/min Total bilirubin ≤ 2 time upper limit normal ( ULN ) ( unless due Gilbert 's disease malignancy ) ALT AST ≤ 4 time ULN DLCO ≥ 40 % FEV1/FVC ratio ≥ 50 % predict Cardiac ejection fraction ≥ 40 % Not pregnant nursing Fertile patient must use effective contraception Not receive supplementary continuous oxygen No NYHA grade IIIV cardiac disease HIV negative No evidence active hepatitis B ( i.e. , positive HBsAg and/or positive HBeAg high copy number quantitative RNA test ) hepatitis C No active uncontrolled infection immediate lifethreatening condition No uncontrolled medical illness ( e.g. , uncontrolled systemic hypertension diabetes ) PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior cytoreductive chemotherapy irradiation area bulky disease allow , determine primary physician consultation study investigator No concurrent antitumor therapy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
</DOC>